File:Immunotherapy + Durvalumab + Pembrolizumab + Ipilimumab + Atezolizumab mechanism of action.jpg

Original file(1,694 × 939 pixels, file size: 164 KB, MIME type: image/jpeg)

Summary

Description
English: Immunotherapy + Durvalumab + Pembrolizumab + Ipilimumab + Atezolizumab mechanism of action
Date
Source Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals 2020, 13(11), 373; https://doi.org/10.3390/ph13110373
Author Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya 3ORCID

Licensing

w:en:Creative Commons
attribution share alike
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
You are free:
  • to share – to copy, distribute and transmit the work
  • to remix – to adapt the work
Under the following conditions:
  • attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.

Captions

Immunotherapy mechanism of action

Items portrayed in this file

depicts

9 November 2021

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current03:15, 10 November 2021Thumbnail for version as of 03:15, 10 November 20211,694 × 939 (164 KB)SannecolaUploaded a work by Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya 3ORCID from Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals 2020, 13(11), 373; https://doi.org/10.3390/ph13110373 with UploadWizard
The following pages on the English Wikipedia use this file (pages on other projects are not listed):

Global file usage

The following other wikis use this file: